Clopidogrel Bisulfate
Product Images NDC 53808-0806

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 53808-0806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Clopidogrel 75mg Sun Pharm)

Clopidogrel 75 mg tablet bottle label showing quantity of 60 tablets. Includes manufacturer SUN PHARMA and packager DOH Central Pharmacy, Tallahassee, FL. The label lists lot number JKL4405A and expiration date 07/31/2013. Marked RX Only.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of clopidogrel bisulfate, showing its bicyclic thienopyridine core with a chlorine-substituted phenyl group and a methyl ester functional group, along with the sulfate (H2SO4) component as indicated.*

FDA Label Image

Figure1 (Figure1)

A figure illustrating the exposure to clopidogrel active metabolite following multiple doses of clopidogrel 75 mg alone or combined with proton pump inhibitors (PPIs). The chart shows the effect on active metabolite AUC with mean and 90% confidence intervals for four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis represents the change relative to clopidogrel administered alone, ranging from 0.4 to 1.4.*

FDA Label Image

Figure2 (Figure2)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' showing cumulative event rates (%) on the vertical axis and months of follow-up (0-12) on the horizontal axis. The graph compares two groups: placebo (+ aspirin) and clopidogrel (+ aspirin), illustrating lower event rates in the clopidogrel group over time. A p-value of 0.00009 is indicated, noting the use of other standard therapies as appropriate.*

FDA Label Image

Figure3 (Figure3)

A forest plot titled 'Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study.' The plot compares Clopidogrel plus aspirin versus placebo plus aspirin across multiple baseline characteristics and concomitant therapies, showing hazard ratios with 95% confidence intervals and indicating which treatment is favored.*

FDA Label Image

Figure4 (Figure4)

A cumulative event rate graph showing percentage dead before first discharge over 28 days since randomization in the COMMIT study. Two curves compare death rates for placebo and Clopidogrel, with placebo resulting in 1845 deaths (8.1%) and Clopidogrel in 1726 deaths (7.5%), indicating a 7% proportional risk reduction (p = 0.03). All treated patients received aspirin.*

FDA Label Image

Figure5 (Figure5)

A cumulative event rate line graph from the COMMIT study showing the combined endpoint of re-infarction, stroke, or death up to 28 days post-randomization. The y-axis shows the percentage of patients with events before first discharge, and the x-axis shows days since randomization. Separate lines compare placebo and Clopidogrel groups, with event percentages and risk reduction noted.*

FDA Label Image

Figure6 (Figure6)

A forest plot from the COMMIT Study showing the effects of adding Clopidogrel to Aspirin across various baseline and concomitant medication subgroups. The chart compares event percentages, odds ratios with confidence intervals for Clopidogrel and placebo groups by sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. It also includes heterogeneity tests and proportional reduction statistics.*

FDA Label Image

Figure7 (Figure7)

A figure titled 'Effects of Adding Clopidogrel to Aspirin in the Non-Prespecified Subgroups in the COMMIT Study' presents a forest plot comparing event percentages between Clopidogrel and placebo groups across subcategories such as Killip class, previous myocardial infarction, and infarct location. The plot includes odds ratios with confidence intervals, a global heterogeneity test, and a proportional reduction summary for the Clopidogrel group.*

FDA Label Image

Figure8 (Figure8)

A line graph titled 'Fatal or Non-Fatal Vascular Events in the CAPRIE Study' showing cumulative event rates (%) over months of follow-up up to 36 months. Two lines represent event rates for Aspirin and Clopidogrel, with the Clopidogrel line slightly lower. The graph includes a p-value of 0.045 indicating statistical comparison.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.